IGC Pharma
5 hedge funds and large institutions have $276K invested in IGC Pharma in 2014 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, reducing their positions, and 1 closing their positions.
17% less funds holding
Funds holding: 6 → 5 (-1)
24% less capital invested
Capital invested by funds: $363K → $276K (-$87K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$24.1K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$4.48K |
| 3 |
U
UBS
Zurich,
Switzerland
|
+$1.64K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$81 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$33K |
IGC Hedge Fund Activity: Q1 2014 in Review
5 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q1 2014, worth a combined $276K — down 24% from $363K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of IGC and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 4 added.
The largest buyer was Citadel Advisors, adding an estimated $24.1K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $33K sold.
- 5 institutional investors held IGC Pharma (IGC) as of Q1 2014, down from 6 in Q4 2013.
- Funds reported $276K of IGC Pharma stock for Q1 2014, down 24% quarter-over-quarter.
- 0 funds opened new IGC Pharma positions in Q1 2014 and 1 closed out, a net change of -1 holder.
- The largest IGC Pharma buyer in Q1 2014 was Citadel Advisors, an estimated $24.1K added.
- The largest IGC Pharma seller in Q1 2014 was Virtu KCG Holdings, an estimated $33K sold.
Based on aggregated 13F filings for Q1 2014.